Observational Multicenter Non-interventional Study on COPD Patients Treatment Strategies at the Time of Hospital Discharge and Within 12 Months of Follow-up on an Outpatient Primary Care Basement

NCT ID: NCT02346292

Last Updated: 2017-12-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1250 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-03-31

Study Completion Date

2016-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is an observational multicenter descriptive study. It is planned to enroll approximately 1250 subjects with severe and very severe COPD hospitalized for the reason of COPD exacerbation into departments of pulmonology or therapy. The study will be conducted in approximately 20-25 institutions of treatment and prevention in Russian Federation and will include about 50 to 60 subject at each clinical site.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study is an observational multicenter descriptive study. It is planned to enroll approximately 1000 subjects with severe and very severe COPD hospitalized for the reason of COPD exacerbation into departments of pulmonology or therapy. The study will be conducted in approximately 20-25 institutions of treatment and prevention in Russian Federation and will include about 50 to 60 subject at each clinical site.

This is an observational study, so there is no treatment protocol or subjects' management recommendations required. The study subjects receive medical treatment according to the routine practice for their disease in Russian Federation. A subject's participation in this clinical study should not affect character and amount of care provided according to the routine clinical practice.

The study includes 5 clinical visits: Study Enrolment Visit, Month 3 Visit, Month 6 visit, Month 9 Visit, Month 12 visit / End of Study Visit.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COPD

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

COPD Spirometry severe and very severe COPD COPD exacerbations therapy schemes therapy changes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Patients of both genders aged 40 years and older, smokers, with smoking history more than 10 pack-years, with severe and very severe COPD who were hospitalized with COPD exacerbation

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed informed consent . Men and women at least 40 years old, with smoking history more than 10 pack-years.
* Hospitalization for the reason of COPD exacerbation (exacerbation defined as acute condition, different from typical fluctuations of general condition and requiring change of therapy).
* Diagnosis of severe or very severe COPD based on final spirometry (performed in a standardized manner using salbutamol 400 mg), or history of diagnosis of severe or very severe COPD based on spirometry performed during 6 months before the hospitalization.

Exclusion Criteria

* Participation in any interventional study.
* Concomitant respiratory diseases, i.e. confirmed or suspected malignancy or any other serious condition, including lung tumor, lung fibrosis, interstitial lung disease, tuberculosis, sarcoidosis.
* Patient is unable or unwilling to complete questionnaires, unable to understand study procedures, or other reasons which, in the investigator's opinion, could affect study procedures performance.
Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alexander Bedenkov, Medical Director

Role: STUDY_DIRECTOR

AstraZeneca

Sergey Avdeev, MD, PHD

Role: PRINCIPAL_INVESTIGATOR

Federal State Institution "Scientific Research Institute of Pulmonology" FMBA of Russia

Andrey Belevsky, PHD

Role: PRINCIPAL_INVESTIGATOR

Federal State Institution "Scientific Research Institute of Pulmonology" FMBA of Russia

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Barnaul, , Russia

Site Status

Research Site

Blagoveshchensk, , Russia

Site Status

Research Site

Chelyabinsk, , Russia

Site Status

Research Site

Cherepovets, , Russia

Site Status

Research Site

Chita, , Russia

Site Status

Research Site

Gatchina, , Russia

Site Status

Research Site

Izhevsk, , Russia

Site Status

Research Site

Kazan', , Russia

Site Status

Research Site

Kemerovo, , Russia

Site Status

Research Site

Kirov, , Russia

Site Status

Research Site

Krasnodar, , Russia

Site Status

Research Site

Krasnoyarsk, , Russia

Site Status

Research Site

Kursk, , Russia

Site Status

Research Site

Moscow, , Russia

Site Status

Research Site

Naberezhnye Chelny, , Russia

Site Status

Research Site

Novokuznetsk, , Russia

Site Status

Research Site

Novosibirsk, , Russia

Site Status

Research Site

Omsk, , Russia

Site Status

Research Site

Oryol, , Russia

Site Status

Research Site

Petrozavodsk, , Russia

Site Status

Research Site

Rostov-on-Don, , Russia

Site Status

Research Site

Ryazan, , Russia

Site Status

Research Site

Saint Petersburg, , Russia

Site Status

Research Site

Seversk, , Russia

Site Status

Research Site

Smolensk, , Russia

Site Status

Research Site

Ufa, , Russia

Site Status

Research Site

Voronezh, , Russia

Site Status

Research Site

Yakutsk, , Russia

Site Status

Research Site

Yaroslavl, , Russia

Site Status

Research Site

Yekaterinburg, , Russia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Russia

Related Links

Access external resources that provide additional context or updates about the study.

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NIS-RRU-XXX-2014/1

Identifier Type: -

Identifier Source: org_study_id